About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiary Shandong Taibang, is currently the only plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province with a population of 93 million. The Company is engaged primarily in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Plasma-based Human Albumin is used mainly to increase blood volume while Immunoglobulin is used for disease prevention and treatment.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating to
the business of China Biologic Products, Inc. and its subsidiary companies.
All statements, other than statements of historical fact included herein are
"forward-looking statements," including statements regarding: the Company's
proposed acquisitions and acquisition strategy and the benefits of proposed
acquisitions, including the expected impact on the Company's 2009 revenues and
net income; the ability of the Company to achieve its commercial objectives;
the business strategy, plans and objectives of the Company and its
subsidiaries; and any other statements of non-historical information. These
forward-looking statements are often identified by the use of forward-looking
terminology such as "believes," "expects" or similar expressions, involve
known and unknown risks and uncertainties. Although the Company believes that
the expectations reflected
|SOURCE China Biologic Products, Inc.|
Copyright©2009 PR Newswire.
All rights reserved